69716-04-7

Usage

Uses

Used in Pharmaceutical Industry:
2-(6-Hydroxy-1-benzofuran-3-yl) Acetic Acid, 97 is used as a reactant in the synthesis of dihydrobenzofuran derivatives, which have potential applications as potent and orally available GPR40/FFA1 agonists. These agonists play a crucial role in modulating glucose homeostasis and insulin secretion, making them valuable for the treatment of type 2 diabetes and related metabolic disorders.
In the synthesis process, 2-(6-Hydroxy-1-benzofuran-3-yl) Acetic Acid, 97 is combined with other chemical moieties to form the desired dihydrobenzofuran compound. 2-(6-HYDROXY-1-BENZOFURAN-3-YL) ACETIC ACID, 97, 6-[4''-(2-ethoxyethoxy)-2'',6''-dimethylbiphenyl-3-yl]methoxy-2,3-dihydro-1-benzofuran-3-yl)acetic acid, exhibits high affinity and selectivity for the GPR40/FFA1 receptor, making it a promising candidate for further research and development in the field of diabetes management.
Overall, 2-(6-Hydroxy-1-benzofuran-3-yl) Acetic Acid, 97 is an essential component in the development of innovative pharmaceutical agents, particularly in the area of diabetes treatment. Its unique chemical properties and reactivity make it a valuable building block for the synthesis of potent and effective GPR40/FFA1 agonists, which have the potential to improve the lives of millions of people living with type 2 diabetes and related metabolic conditions.

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 108-46-3 recorcinol 
• 161798-25-0 4-(bromomethyl)-7-hydroxy-2H-chromen-2-one 
• 25392-41-0 4-chloromethyl-7-hydroxycoumarin 

Downstream Products

• 805250-17-3 (6-hydroxy-2,3-dihydro-benzofuran-3-yl)-acetic acid methyl ester 
• 1356599-30-8 {6-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]-2,3-dihydro-benzofuran-3-yl}acetic acid 
• 1356600-64-0 methyl {6-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]-2,3-dihydro-benzofuran-3-yl}acetate 
• 1000414-38-9 methyl ((3S)-6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate 
• 945774-05-0 C₂₆H₂₁F₃O₅ 
• 945774-04-9 C₂₆H₂₁F₃O₅ 
• 945774-03-8 C₂₆H₂₁F₃O₅ 
• 779205-37-7 {6-[5-(4-Trifluoromethyl-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid methyl ester 
• 779200-80-5 {6-[5-(4-Chloro-phenyl)-isoxazol-3-ylmethoxy]-benzofuran-3-yl}-acetic acid methyl ester 
• 945773-91-1 C₂₃H₁₈F₃NO₄S 
• 69716-05-8 2-(6-methoxy-1-benzofuran-3-yl)acetic acid 

Relevant academic research and scientific papers

Compound with glucose-reducing and lipid-regulating effects as well as preparation and application thereof

The invention discloses a compound with glucose-reducing and lipid-regulating effects as well as a preparation and application thereof. The compound with glucose-reducing and lipid-regulating effectsis a compound with structures as shown in a formula I and a formula II and a pharmaceutically acceptable salt, wherein the structures as shown in the formula I and the formula II are specifically shown in the specification. The preparation is a tablet, a capsule, powder, a pill or an injection prepared by adding pharmaceutically acceptable auxiliary materials into the compound with the glucose-reducing and lipid-regulating effects. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparing an FFA1/PPARdelta dual agonist. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparation of drugs for preventing and/or treating glucose metabolic disorder and/or lipid metabolic disorder diseases. The compound and the medicinal salt thereof can be potentially used for treating or preventing diabetes, hyperlipidemia, fatty liver and other related metabolic syndromes, and have wide development prospects.

The Fragment-Based Development of a Benzofuran Hit as a New Class of Escherichia coli DsbA Inhibitors

A fragment-based drug discovery approach was taken to target the thiol-disulfide oxidoreductase enzyme DsbA from Escherichia coli (EcDsbA). This enzyme is critical for the correct folding of virulence factors in many pathogenic Gram-negative bacteria, and small molecule inhibitors can potentially be developed as anti-virulence compounds. Biophysical screening of a library of fragments identified several classes of fragments with affinity to EcDsbA. One hit with high mM affinity, 2-(6-bromobenzofuran-3-yl)acetic acid (6), was chemically elaborated at several positions around the scaffold. X-ray crystal structures of the elaborated analogues showed binding in the hydrophobic binding groove adjacent to the catalytic disulfide bond of EcDsbA. Binding affinity was calculated based on NMR studies and compounds 25 and 28 were identified as the highest affinity binders with dissociation constants (KD) of 326 ± 25 and 341 ± 57 μM respectively. This work suggests the potential to develop benzofuran fragments into a novel class of EcDsbA inhibitors.

Synthesis and preliminary evaluation of benzofuran-oxadiazole conjugates as potential antitubercular agents

In the present study, a series of benzofuran-oxadiazole conjugates 7(a-o) was designed, synthesized and characterized through IR,1H NMR,13C NMR and mass spectral data. All the compounds were screened for preliminary antitubercular activity against Mycobacterium phlei and Mycobacterium tuberculosis H37RV. Among all the target compounds, the compound possessing chlorine (7k, MIC 1.56 μg/mL) and bromine (7m, MIC 1.56 μg/mL) on 6th position of benzofuran showed highest activity against Mycobacterium phlei. Whereas, bromine on either 5th position (7l, MIC 3.125 μg/mL) or 6th position (7m MIC 3.125 μg/mL) on benzofuran exhibited highest activity for Mycobacterium tuberculosis (H37 RV).

Biphenyl heterocyclic derivatives, their preparation and their use as medicaments (by machine translation)

The present invention relates to a novel biphenyl heterocyclic derivative represented by a general formula (I) and a preparation method thereof and use of a pharmaceutical composition containing the derivative for preparation of a drug for treating diabetes. The biphenyl heterocyclic derivative has extremely excellent hypoglycemic activity in vivo, and excellent in vivo safety and low liver toxicity risk of the compound having such a structure are unexpectedly found, and the novel biphenyl heterocyclic derivative may be used for preventing or treating diabetes.

(S) - 2 - (2,3-dihydrobenzo-furan-3-yl) acetic acid derivatives, its preparation process and its use in medicine

The invention relates to an (S)-2-(2,3-dihydrobenzofuran-3-radical) acetic acid derivative, a preparation method of the derivative, a medicine composition containing the derivative and the application of the derivative serving as a therapeutic agent, particularly GPR40/FFA1, and particularly provides the (S)-2-(2,3-dihydrobenzofuran-3-radical) acetic acid derivative shown in a general formula (I), and pharmaceutically acceptable salts of the derivative or a prodrug of the derivative. The compound is an agonist of a GPR40/FFA1 receptor and has a good preventive and therapeutic effect on lots of GPR40-mediated diseases, especially diabetes mellitus. The invention also provides a preparation method of the compound.

Aromatic polycyclic carboxylic acid derivatives

The invention belongs to the field of medicine technology, and specifically relates to an aromatic polycyclic carboxylic acid derivative GPR40 receptor agonist with a general formula (I), a pharmaceutically acceptable salt thereof, and an ester or stereoi

Novel oxime ether derivative and preparation method thereof and application of derivative by serving as drug

The invention relates to a novel oxime ether derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The oxime ether derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.

Novel nitrogen-containing heterocyclic derivative and preparation method thereof and application of derivative by serving as drug

The invention relates to a novel nitrogen-containing heterocyclic derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The nitrogen-containing heterocyclic derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.

Efficient and Convenient Method for Synthesis of Benzofuran-3-acetic Acids and Naphthafuran-acetic Acids

Herein, we report an efficient and convenient method for synthesis of benzofuran-3-acetic acids and naphthafuran-acetic acids 5a-p by the reaction of substituted-4-bromomethylcoumarins with aqueous sodium hydroxide at refluxing temperature. The obtained products are characterized by infrared, 1H NMR, 13C NMR, and mass spectral data. Structures 5a and 5e are confirmed by their single x-ray diffraction studies. The advantages of this method are good yields, easy workup, and no chromatographic purifications.

AGONISTS OF GPR40

The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are there-fore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.